Micropulse Laser Therapy for Retinal Conditions
Understanding Micropulse Laser Therapy
Micropulse laser therapy, sometimes called subthreshold micropulse laser (SML), is a retinal laser treatment that delivers energy in tiny, rapid bursts rather than in one continuous beam. Each burst lasts only microseconds. Between bursts, the tissue cools down. This on-and-off pattern is what makes micropulse therapy different from conventional laser photocoagulation, which applies steady heat and can leave visible scars on the retina.
The most commonly used wavelength is 577 nanometers, known as yellow subthreshold micropulse laser (YSML). A retina specialist can adjust the wavelength, power level, pulse duration, spot size, and number of spots to tailor the treatment for each patient and condition.
The short bursts of laser energy stimulate the retinal pigment epithelium (RPE), a layer of cells beneath the retina that supports its health. The laser also activates Muller cells, which are support cells within the retina itself. This stimulation triggers the production of heat-shock proteins, which are natural protective molecules found in many types of cells.
Heat-shock proteins help cells resist stress by blocking pathways that cause inflammation and cell death. Because the energy delivered is below the threshold that causes visible tissue damage, the treatment leaves no retinal scars. Research has shown that micropulse delivery requires four to ten times less energy per pulse compared to the level that would cause visible damage. This results in lower peak power and reduced risk of complications.
Traditional laser photocoagulation applies continuous thermal energy to retinal tissue. This creates small burns that seal leaking blood vessels or destroy abnormal tissue. While effective, conventional laser leaves lasting scars that can affect side vision or central vision if applied near the macula.
Micropulse laser avoids this scarring entirely. The duty cycle, meaning the percentage of time the laser is actually firing, is typically set at just 5%. That means the laser is on for only 5% of each cycle and off for the remaining 95%, giving tissue time to cool. This approach allows a retina specialist to treat the central macula more safely.
Conditions Treated with Micropulse Laser
Diabetic macular edema (DME) is swelling in the macula caused by leaking blood vessels in people with diabetes. DME occurs in about 4% of patients at all stages of diabetic retinopathy (Ophthalmology, 2023). Worldwide, an estimated 18.83 million adults had clinically significant macular edema in 2020. Projections suggest this number may reach 28.61 million by 2045 (AAO, 2022).
Micropulse laser therapy has shown significant effectiveness in reducing macular thickness and improving visual acuity in patients with mild to moderate DME. Research indicates that micropulse monotherapy works best when the central foveal thickness is 400 micrometers or less. For patients with more severe swelling, a retina specialist may combine micropulse therapy with anti-VEGF injections for better results.
Central serous chorioretinopathy (CSCR) is a condition where fluid collects under the retina, causing blurred or distorted central vision. It most commonly affects younger adults, particularly men. In chronic cases where the fluid does not resolve on its own, treatment may be needed.
A randomized controlled study found that patients with chronic CSCR experienced similar improvements at 12 months. Both subthreshold micropulse laser therapy and half-dose photodynamic therapy (PDT) produced comparable gains in anatomy and visual function. However, PDT may offer faster initial resolution of the fluid beneath the retina. Micropulse laser remains a valuable option because it avoids the potential side effects associated with PDT.
Retinal vein occlusion (RVO) occurs when a vein in the retina becomes blocked, leading to swelling and bleeding. Macular edema from branch retinal vein occlusion (BRVO) is one of the conditions where micropulse laser therapy has shown meaningful benefit. Studies have demonstrated reductions in macular thickness and improvements in visual acuity in these patients.
In many cases, micropulse therapy is used alongside anti-VEGF injections such as Eylea (aflibercept) or Avastin (bevacizumab), which is used off-label for eye conditions. The combination approach may help reduce the overall number of injections needed over time.
Who May Benefit and Risk Factors
Micropulse laser therapy tends to work best for patients with mild to moderate macular edema. Research has shown that patients with a central retinal thickness below 400 micrometers respond most favorably. Many patients are considered for micropulse therapy after receiving an initial series of three anti-VEGF loading doses and showing a partial response.
A retina specialist will evaluate each patient individually to determine whether micropulse laser is appropriate. Factors such as the type of condition, the severity of swelling, and previous treatments all play a role in this decision.
The severity of macular edema influences how well micropulse laser works. Studies comparing patients with central foveal thickness at or below 400 micrometers to those above found notable differences. The less severe group had better outcomes with micropulse monotherapy. Patients with more severe edema may still benefit from micropulse treatment. However, they typically do best with a combination approach that includes anti-VEGF injections rather than standalone therapy.
The conditions treated by micropulse laser each have their own risk factors. For diabetic macular edema, the primary risk factors include poorly controlled blood sugar, high blood pressure, high cholesterol, and longer duration of diabetes. For CSCR, stress, corticosteroid use, and certain personality types may increase risk. Retinal vein occlusion is associated with high blood pressure, diabetes, glaucoma, and blood clotting disorders.
Managing these underlying health conditions can help slow the progression of retinal disease. It may also improve the response to micropulse laser therapy.
What Happens During the Procedure
Before micropulse laser therapy, a retina specialist will perform a thorough eye examination. This typically includes optical coherence tomography (OCT), which creates detailed cross-section images of the retina to measure swelling. Fluorescein angiography, a test that uses dye to photograph blood vessels in the retina, may also be performed to identify areas of leakage.
The specialist will use these images to plan the treatment area and determine the appropriate laser settings. Pupil-dilating eye drops will be applied before the procedure.
Micropulse laser therapy is performed in the office of a retina specialist. Numbing eye drops are placed on the eye. A special contact lens is then placed on the surface of the eye to focus the laser beam onto the retina.
The International Retinal Laser Society (LIGHT) recommends standardized settings for safety and effectiveness. These include a 577-nanometer wavelength, 200-micrometer spot size, 200-millisecond pulse duration, 400 milliwatts of power, and a a moderate percentage duty cycle. The laser is applied over the affected area of the macula. The procedure typically takes 10 to 20 minutes. Most patients report little to no discomfort during treatment.
There is usually no downtime after micropulse laser therapy. Vision may be slightly blurry for a few hours due to the dilating drops and the contact lens used during the procedure. Most patients can return to normal activities the same day.
A retina specialist will schedule follow-up visits to monitor the response using OCT imaging. Because micropulse laser does not leave visible scars, the treatment effect is tracked by measuring changes in retinal thickness and visual acuity over time. Some patients may need repeat treatments.
Treatment Outcomes and Effectiveness
Research has consistently shown that micropulse laser therapy can reduce macular thickness, help the retina absorb excess fluid, and improve visual acuity in patients with DME and macular edema from BRVO. A key advantage is the absence of retinal scarring, which means the treatment can be safely repeated if needed.
For mild to moderate macular edema with retinal thickness below 400 micrometers, micropulse therapy alone has proven to be a safe and effective approach. The International Retinal Laser Society has endorsed this as a viable first-line or adjunctive treatment in appropriate cases.
One of the most promising findings in recent research is that combining micropulse laser therapy with anti-VEGF injections can reduce the total number of injections patients need. A meta-analysis found that patients receiving both treatments required an average of 2.22 fewer injections per year compared to injections alone. This difference was statistically significant.
Anti-VEGF medications commonly used alongside micropulse therapy include:
- Eylea (aflibercept), typically given every 4 to 8 weeks after a loading phase
- Lucentis (ranibizumab), typically given every 4 weeks
- Avastin (bevacizumab), used off-label for eye conditions, typically given every 4 to 6 weeks
- Vabysmo (faricimab), a bispecific antibody that may extend to every 16 weeks after a loading phase
Fewer injections can mean fewer office visits, lower treatment burden, and reduced risk of injection-related side effects. A retina specialist can determine whether a combination approach is appropriate based on the individual patient's condition and response.
Micropulse laser therapy has an excellent safety record. Very few complications have been reported in the medical literature. Because the laser energy stays below the damage threshold, there are no lasting scars, burns, or structural changes to the retina in properly performed treatments.
The most significant concern is not overtreatment but undertreatment. Because there are no visible marks to confirm the laser reached the tissue, some patients may not respond adequately. In these cases, treatment settings may be adjusted, or additional sessions may be recommended. Ongoing research continues to fine-tune optimal settings so that more patients benefit from each treatment session.
Living with a Retinal Condition
Micropulse laser therapy is not a one-time fix for retinal conditions. Most patients require ongoing monitoring and may need repeat treatments or continued anti-VEGF injections. The goal of treatment is to reduce swelling, preserve vision, and slow disease progression.
Patients should understand that visual improvement may be gradual. Some patients experience meaningful gains in visual acuity, while others may see stabilization of their current vision. Both outcomes are considered successful in preventing further vision loss.
For patients with diabetic macular edema, controlling blood sugar, blood pressure, and cholesterol levels is essential. These factors directly affect the health of retinal blood vessels and can influence how well any treatment works. Working closely with a primary care physician or endocrinologist can support better retinal outcomes.
For patients with CSCR, reducing stress and avoiding corticosteroid medications when possible may help prevent recurrence. A retina specialist can work with other physicians to find alternative medications if corticosteroids are contributing to the condition.
Regular follow-up with a retina specialist is critical for anyone undergoing micropulse laser therapy. OCT imaging at follow-up visits allows the specialist to track changes in retinal thickness and determine whether additional treatment is needed. Skipping appointments can allow swelling to worsen without the patient noticing changes in vision.
When to See a Retina Specialist
Anyone with diabetes, a history of retinal vein occlusion, or a diagnosis of central serous chorioretinopathy should have regular dilated eye examinations. An optometrist or general ophthalmologist can screen for retinal changes and refer patients to a retina specialist when needed.
Patients who have been diagnosed with macular edema should discuss all available treatment options with their retina specialist, including micropulse laser therapy.
Certain symptoms require immediate attention. See a retina specialist or go to the emergency room immediately if you experience any of the following:
- Sudden increase in floaters
- Flashes of light in your vision
- A curtain or shadow spreading across your field of vision
- Sudden vision loss in one eye
These symptoms may indicate a retinal emergency such as a retinal detachment and should not be ignored or delayed.
Questions and Answers
Most patients report little to no discomfort during micropulse laser therapy. Numbing eye drops are applied before the procedure, and the laser energy is delivered at levels well below the threshold that causes tissue damage. Some patients feel a mild warmth or see brief flashes of light during treatment. The procedure does not require sedation or general anesthesia, and patients typically return to normal activities the same day.
The number of sessions varies depending on the condition being treated and how well the retina responds. Some patients see improvement after a single session, while others may need two or more treatments over several months. Because micropulse laser does not scar the retina, it can be safely repeated. A retina specialist will use OCT imaging to monitor progress and determine if additional sessions are needed.
For some patients with mild to moderate macular edema, micropulse laser therapy may be sufficient on its own. However, many patients benefit from a combination of micropulse laser and anti-VEGF injections. Research shows that adding micropulse therapy can reduce the number of injections needed by an average of about two per year. Whether micropulse laser can serve as a standalone treatment depends on the severity of the condition and the individual response. A retina specialist will recommend the best approach for each situation.
When performed with proper settings, micropulse laser therapy does not cause lasting scars, burns, or structural damage to the retina. This is one of its primary advantages over traditional laser photocoagulation. The energy is delivered below the visible damage threshold, stimulating cellular healing responses without destroying tissue. The main risk with this approach is undertreatment rather than overtreatment. Adjustments to settings can be made in follow-up sessions if needed.
Many patients experience improvements in visual acuity and reductions in macular swelling after micropulse laser therapy. However, results vary from person to person. Some patients see measurable visual gains, while others experience stabilization that prevents further vision loss. The response depends on factors such as the severity of the condition, the duration of swelling before treatment, and overall health. A retina specialist will set realistic expectations and monitor progress over time.